New knee pain drug AD-211 enters Mid-Stage trial
NCT ID NCT07550231
First seen May 02, 2026 · Last updated May 02, 2026
Summary
This study tests a new drug called AD-211 for people with knee osteoarthritis. The goal is to find the best dose to reduce pain during activity. About 200 participants will receive either AD-211 or a placebo in a double-blind setup, meaning neither they nor their doctors will know who gets the real drug. The main measure is pain change from the start of the study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS OF THE KNEES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.